Champions Enterprise Value Over E B I T D A from 2010 to 2024
| CSBR Stock | USD 4.52 0.21 4.87% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (13.95) | Current Value (13.26) | Quarterly Volatility 114.95895765 |
Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 38.3 K or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 1.24, Dividend Yield of 0.0033 or Days Sales Outstanding of 72.79. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.
Champions | Enterprise Value Over E B I T D A |
Latest Champions Oncology's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Champions Oncology over the last few years. It is Champions Oncology's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Champions Oncology's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Champions Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 23.30 | |
| Coefficient Of Variation | 493.34 | |
| Mean Deviation | 67.24 | |
| Median | (3.74) | |
| Standard Deviation | 114.96 | |
| Sample Variance | 13,216 | |
| Range | 517 | |
| R-Value | 0.10 | |
| Mean Square Error | 14,085 | |
| R-Squared | 0.01 | |
| Significance | 0.72 | |
| Slope | 2.61 | |
| Total Sum of Squares | 185,018 |
Champions Enterprise Value Over E B I T D A History
About Champions Oncology Financial Statements
Champions Oncology shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Champions Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (13.95) | (13.26) |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
| 0.49 | VERV | Verve Therapeutics | PairCorr |
| 0.44 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.38 | EQ | Equillium | PairCorr |
| 0.35 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.